Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Kezar Life Sciences, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 7.39M shares outstanding
USKezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies.
Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer.
The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology.
The firm was founded in 2015 and is headquartered in South San Francisco, California.
Leadership
Christopher Kirk, Ph.D.
Chief Executive Officer and Director
Franklin Berger
Director
Graham Cooper
Chairman
John Fowler
Director
Employees
55
Country
US
Sector
Healthcare
Website
kezarlifesciences.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Belsky Marc | Chief Financial Officer | Withholding/Transfer | 6.0K | -- | May 11, 2026 |
 Schiller Mark C. | Chief Legal Officer | Withholding/Transfer | 2.7K | -- | May 11, 2026 |
 Kirk Christopher J. | CEO | Withholding/Transfer | 43.1K | -- | May 11, 2026 |
 Kauffman Michael | Director | Withholding/Transfer | 6.4K | -- | May 11, 2026 |
 BERGER FRANKLIN M | Director | Withholding/Transfer | 89.1K | -- | May 11, 2026 |
 Fowler John Franklin | Director | Withholding/Transfer | 39.4K | -- | May 11, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Suvretta Capital Management, LLC · filed Feb 2024 | 716.8K | 9.7% | 13G |
Equal Talent Investments Limited · may incl. warrants· filed Mar 2025 | 616.5K | 8.3% | 13D |
VANGUARD GROUP INC | 341.4K | 4.6% | 13F |
Prosight Management, LP · filed Feb 2024 | 336.5K | 4.6% | 13G |
Millennium Management LLC · filed Jan 2024 | 292.8K | 4.0% | 13G |
OrbiMed Capital LLC · filed Feb 2024 | 192.7K | 2.6% | 13G |
Stonepine Capital Management, LLC · filed Feb 2026 | 156.2K | 2.1% | 13G |
BlackRock, Inc. · may incl. warrants· stale · filed Jul 2024 | 83.0K | 1.1% | 13G |
CIBC Private Wealth Group LLC | 100 | 0.0% | 13F |
Insiders
- Belsky MarcChief Financial Officer
- Schiller Mark C.Chief Legal Officer
- Kirk Christopher J.CEO
- Kauffman MichaelDirector
- BERGER FRANKLIN MDirector
- Fowler John FranklinDirector
- Chiang Pichi LuoSVP, Corporate Controller
- Wallace CourtneyDirector
- Klearman MickiDirector
- COOPER GRAHAM KDirector
Top institutional holders
based on 7.39M shares outstanding
US30d Avg
--
60d Avg
--
90d Avg
--